UTHR vs. BPMC, RETA, TEVA, BBIO, BIIB, ALNY, BMRN, NBIX, INCY, and RGEN
Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Blueprint Medicines (BPMC), Reata Pharmaceuticals (RETA), Teva Pharmaceutical Industries (TEVA), BridgeBio Pharma (BBIO), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Incyte (INCY), and Repligen (RGEN). These companies are all part of the "medical" sector.
Blueprint Medicines (NASDAQ:BPMC) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, community ranking, institutional ownership and dividends.
Blueprint Medicines has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500.
United Therapeutics received 53 more outperform votes than Blueprint Medicines when rated by MarketBeat users. However, 67.84% of users gave Blueprint Medicines an outperform vote while only 61.84% of users gave United Therapeutics an outperform vote.
United Therapeutics has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
94.1% of United Therapeutics shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by company insiders. Comparatively, 12.5% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
United Therapeutics has a net margin of 42.05% compared to United Therapeutics' net margin of -102.15%. Blueprint Medicines' return on equity of 18.72% beat United Therapeutics' return on equity.
Blueprint Medicines currently has a consensus price target of $108.00, indicating a potential upside of 3.43%. United Therapeutics has a consensus price target of $309.44, indicating a potential upside of 11.96%. Given Blueprint Medicines' stronger consensus rating and higher possible upside, analysts clearly believe United Therapeutics is more favorable than Blueprint Medicines.
In the previous week, United Therapeutics had 6 more articles in the media than Blueprint Medicines. MarketBeat recorded 14 mentions for United Therapeutics and 8 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.80 beat United Therapeutics' score of 0.35 indicating that United Therapeutics is being referred to more favorably in the news media.
Summary
United Therapeutics beats Blueprint Medicines on 14 of the 18 factors compared between the two stocks.
Get United Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
United Therapeutics Competitors List
Related Companies and Tools
